Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $5.94B · View financials
Snapshot Sep 4, 4:00 PM ET
Decision snapshot: QLYS stock price vs VRTX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at VRTX's multiple
Needs VRTX P/E.
Implied fair value · at QLYS's multiple
Needs QLYS P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: QLYS FY 2025 (ended Dec 31, 2025) · VRTX FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 98% equity / 2% debt · EV / Revenue 8.64x · EV / EBITDA 23.19x
Capital structure 97% equity / 3% debt · EV / Revenue 11.34x · EV / EBITDA 27.98x
VRTX carries the larger enterprise value at $136.04B against $5.78B; QLYS trades on the lower EV / Revenue multiple (8.64x vs 11.34x); QLYS on the lower EV / EBITDA (23.19x vs 27.98x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Qualys, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
VERTEX PHARMACEUTICALS INC / MA · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.17x
0.23x
Net debt / EBITDA
Leverage against operating earnings
-0.62x
-0.49x
Cash and equivalents
Liquid reserves on the balance sheet
$250.26M
$6.61B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
CrowdStrike Holdings, Inc.
QLYS vs CRWD
Okta, Inc.
QLYS vs OKTA
Gen Digital Inc.
QLYS vs GEN
Palo Alto Networks Inc
QLYS vs PANW
Fortinet, Inc.
QLYS vs FTNT
Zscaler, Inc.
QLYS vs ZS
AMGEN INC
QLYS vs AMGN
Gilead Sciences, Inc.
QLYS vs GILD
BIOGEN INC.
QLYS vs BIIB
Moderna, Inc.
QLYS vs MRNA
Illumina, Inc.
QLYS vs ILMN
$95.20M
$4.23B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
